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Abstract
Introduction
Magnesium sulfate (MgSO4) is the drug of choice for the prevention and control of seizures
in the management of severe preeclampsia/eclampsia. Several barriers have been identi-
fied in the use of MgSO4, especially in low and middle-income settings.
Objective
To describe the obstetrician’s perception on possible reasons for underutilizing magnesium
sulfate to treat preeclampsia/eclampsia.
Method
A qualitative clinical study, based on phenomenological reference by semi-structured inter-
views and open-ended discussions with obstetricians of the public healthcare system in pri-
mary care units (PCU) and referral maternity hospitals (RMH), in a southeastern Brazilian
city.
Results
Fear of drug toxicity was the major cause for not prescribing the medication in PCU. Fear
was justified by insufficient technical, structural and organizational resources of healthcare
facilities and by a shortage of physicians properly trained for adequate drug use.
Conclusion
Fear of toxicity of magnesium sulfate was the main barrier towards timely and proper drug
use. Periodic skill development and training of obstetricians, along with integration of the
medical team in the work environment may contribute to decrease fear, ensuring safety of
drug prescription and thus possibly reducing adverse outcomes related to PE.
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Introduction
Preeclampsia and eclampsia are among the three main causes of maternal death worldwide,
affecting approximately 4.6% and 1.4% of all births, respectively [1,2]. Eclampsia is currently
the main cause of maternal death in Brazil [3].
Magnesium sulfate (MgSO4) is one of the main interventions for the control and prevention
of eclamptic seizures, with a good patient safety profile [4, 5]. The World Health Organization
(WHO) has already acknowledged and recommended the use of magnesium sulfate as a strat-
egy to reduce maternal morbidity and mortality [6]. There are two distinct drug regimens for
the effective and safe use of magnesium sulfate, recommended by WHO and other interna-
tional organizations. The first is given exclusively by the intravenous route (IV) (Zuspan,
1966) [7] and the second is a mixture of intravenous (IV) and intramuscular (IM) (Pritchard,
1955) [8] administration. The use of magnesium sulfate is allowed in a non-hospital setting,
such as primary care facilities, especially considering the loading dose [9–11].
In Brazil, studies have reported high coverage of MgSO4, including 68% among women
with severe maternal morbidity due to hypertensive causes [12], and 94% to 100% of women
with eclampsia [13,14]. Although the use of the medication is extensive, maternal mortality
from this cause still remains elevated in the country. The same has been shown in other studies
worldwide, especially in low and middle income settings [14], suggesting that other barriers
might be playing a role, such as inadequate time of drug prescription, lack of training, no evi-
dence-based clinical protocols, and fear of toxicity [15–18].
Our group has previously conducted a general situational analysis on availability and use of
MgSO4 for severe preeclampsia and eclampsia in the public health system and demonstrated
that lack of processes integrating urgency/emergency care and specialized obstetric care possi-
bly favors the inadequate use of MgSO4 [19]
The aim of this study was to explore the obstetrician’s perceived justification for underuti-
lizing MgSO4 in severe preeclampsia/eclampsia.
Materials and methods
Study design
This was a qualitative clinical study using phenomenological methodology [20]. Experience
was studied from a subject’s and subjective perspective [21–23], in order to reveal causal rela-
tionships between the phenomenon and the individual who gained the experience [24]. We
respected the criteria consolidated in qualitative research (COREQ) [22].
Interviews were carried out until repetition of the phenomenon in statements also in mater-
nity. Content saturation was achieved, based on frequency and intensity of certain aspects
present during conversations, with the aims of the study in view. The research study took the
experience presented and reproduced interviewee response. The context was considered, with
rejection of analysis of right or wrong, faithful to segments of conversations, justifications,
hypotheses, and feeling [25].
Research setting and participants
For the current analysis, we considered the municipality of Campinas, in southeastern Brazil
(city selected by convenience). Campinas has 1,080,034 inhabitants and 504,175 women of
reproductive-age [26] with a 16,198 live born for the year 2015 according to the Municipal
Department of Health [27]. The municipality also has good access to antenatal care (78.7% of
pregnant women had seven prenatal visits or more in 2014) and childbirth care (99.6% of
deliveries in the metropolitan region of Campinas occurred in hospitals [27]).
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The healthcare system in Campinas provides coverage for an extended population of four
and a half million inhabitants and is divided into five districts to facilitate planning and man-
agement (North, South, East, Southeast and Northeast), each with about 200,000 inhabitants.
In each district, there is a planned surveillance in healthcare units and referral hospitals
according to neighborhood and complexity. The city has 63 primary care units (PCU) and 3
referral maternity hospitals [28]. PCUs are responsible for primary healthcare with a well-
defined territory and population [28]. Referral maternities are responsible for high-risk and
emergency care during pregnancy, childbirth and postpartum period.
Both healthcare settings were chosen for the interviews: PCUs and referral maternity hospi-
tals. Interviews were carried out by only one interviewer, trained in conducting a semi-struc-
tured interview with free flow of conversation.
Inclusion criteria for the study sample were obstetricians who worked in maternal care in
the public healthcare system in the municipality of Campinas. A sample of obstetricians was
taken from the PCU and maternity hospitals, who were willing to share their experiences,
allowing a deep exploration of aspects relevant to the study. The 63 basic health units were ran-
domized, in order to define a sequence of selected PCUs chosen for interviews with obstetri-
cians, until saturation of content was achieved. A total of 14 PCU were visited, with one
obstetrician interviewed per Unit; two referral Maternities were included, with a total of 16
interviews (10 from one maternity and 6 from the other).
Data collection and analysis
Interviews were conducted during a 6-month period (July to December 2015). The researcher
visited the selected PCU and referral maternity hospitals approaching only obstetricians in
their working environment (there were no refusals to participation in any setting). For data
collection, a semi-structured interview with open-ended questions and a triggering question
was used. However, the interviewees were allowed to engage in free flow of conversation.
Interviews were conducted in a private room at the workplace, lasting in average 20 minutes.
Each obstetrician was asked to express his or her feelings about using MgSO4 in severe pre-
eclampsia/eclampsia, thoughts on this experience and mechanisms to cope with these feelings.
Interviews were identified by letters and numbers indicating the location where they were
held: primary care unit (PCU) and reference maternity hospital (RMH). The identity of the
obstetricians and units visited remained confidential.
Interviews were recorded, guided by the triggering question, and transcribed by Nvivo of
QSR International1 software. Transcriptions were assessed according to analytical technique
of the Bardin content analyses. Initially, skimming and superficial reading of the conversations
were performed. Ideas were identified for the response to research questions. The most com-
monly repeated contents or topics were selected for comparison and category construction
[29, 30].
Data collected on sample characteristics were stored in Excel1 2007 program. This database
was analyzed for logical consistency and inconsistencies identified and further corrected. On
descriptive analysis, the mean, median, standard deviation and minimum and maximum val-
ues were calculated for quantitative variables. Absolute (n) and relative (%) frequencies were
also considered.
Ethical approval
The study was conducted after approval of local IRB (State University of Campinas- CAISM)
and the National Committee of Ethics in Research (Comissão de E´tica em Pesquisa—CEP),
under the letter of approval number 658.325. All principles regulating research on human
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beings according to the Brazilian Health Council (Resolution CNS 466/12) were respected, as
well as the Declaration of Helsinki. A written informed consent was signed by all participants
and their interviews were further recorded.
Results
A total of 14 obstetricians from PCU and 16 from referral maternity hospitals were interviewed
S1 Table. All had completed medical residency in Obstetrics and Gynecology with an average
period of 18 to 19 years since graduation. The mean age of these obstetricians was 44 years
Table 1.
Two sensory categories were defined for analysis: emotional experience and potentiating
factors. Emotional experience is a category that related to feelings of the obstetrician about the
decision to prescribe magnesium sulfate in severe preeclampsia/eclampsia. In the category of
potentiating factors, justifications for not prescribing the drug emerged. These factors were
related to inadequate infra-structure, a shortage of material and equipment, difficulties in
organizing healthcare and work processes in the PCU. Incorrect use of MgSO4 was also
reported Fig 1.
The results are presented according to the constructed categories and workplace of study
participants (PCU and referral maternity hospitals) at the time of the interviews.
Emotional experience
Obstetricians interviewed in PCU believed that adverse events could occur during the use of
MgSO4, and their greatest fear was cardiorespiratory arrest.
“My greatest fear is respiratory arrest. I don’t know how to intubate”. (PCU 5)
“We get really stressed out, afraid that something might happen, afraid of the adverse effects
that may occur. Because here we have little resources, and this makes everything more diffi-
cult”. (PCU 8)
“Because it causes toxicity, decreases respiratory rate and then we can lose her. If she dies, it
will be our fault". (PCU 11)
Obstetricians felt unprepared to deal with complications that may arise from the use of
magnesium sulfate that may trigger lawsuits.
“I switched schedules so that I am not the only attending doctor in the unit, without an Intern
Medicine clinician as support. It has been a long time since I did clinical practice. The Regional
Medical Council makes demands on you. . . We are all alone”. (PCU 7)
Table 1. Characterization of obstetricians interviewed in PCU and maternity hospitals.
Characteristics of participants PCU (n = 14) MATERNITY HOSPITAL (n = 16)
Sex (n)
Male 3 8
Female 11 8
Age in years a 44.35 (31–60) 44,68 (32–62)
Residency in Obstetrics and Gynecology 14 16
Years since graduation a 18.64 (7–35) 19.35 (7–30)
PCU: primary care unit.
a: mean (min–max).
https://doi.org/10.1371/journal.pone.0172602.t001
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“You have to be very careful when filling out a medical chart, when it is time to take risks,
because explanations will be required from you”. (PCU 9)
Concerning the experience of obstetricians working in a hospital, there seemed to be no
fear in prescribing the drug, due to safety in a hospital environment perceived by these profes-
sionals. However, the interviewees in maternity hospitals recognized that prescription of mag-
nesium sulfate generates a feeling of insecurity in the PCU.
“No fear in using the medication here in the hospital. In the hospital the physician orders it, but
the same professional would not administer the drug in a PCU due to lack of resources. (M 10)
“Here we have no difficulty in dealing with this. Our team is highly trained.” (M 11)
“I think it is the fear of managing cardiorespiratory arrest that is so frequently lectured in
conferences: "Revert with gluconate in cardiorespiratory arrest". I think it is highlighted so often
that it leads to fear”. (M 8)
“Because although the medication is easily administered, there is a great myth about the
issue of drug toxicity”. (M 16)
b. Potentiating factors. During interviews, potentiating factors for fear of prescribing
magnesium sulfate were identified in obstetricians from the PCU and referral maternity hospi-
tals. These factors could be associated with underutilization and/or incorrect use of the
medication.
From an obstetricians’s perspective, limited knowledge and little experience in proper use
of MgSO4 potentiated the fear of prescribing this drug.
Fig 1. Process of category construction.
https://doi.org/10.1371/journal.pone.0172602.g001
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“The major difficulty is the lack of knowledge and fear of using the drug. Use it in the hospital
with resources and equipment. In the PCU, its use is impossible”. (PCU1)
“Since we do not use the medication very often, we even have to check the dose. We sort of
know the amount, but need to review the exact dose” (PCU 2).
“Fear of using medication due to complications, unfamiliarity with the sulfate”. (PCU 7)
“The nursing staff receives intensive training and clinical update. This is practically nonex-
istent for the medical staff. . . You receive no clinical update”. (PCU 9)
Unsuitable material, equipment, and infrastructure were also cited by obstetricians from
the PCU as justification for not using the medication in a proper and timely manner. However,
in referral maternity hospitals resources seemed to be fully available.
“Frequently there is no room available for the patient to rest. It is hard, because medication is
lacking” (PCU 1).
“I have nothing here. There is no backup, equipment. Nothing. No monitor, pulse oximeter,
things that we need. . .There isn’t even oxygen here” (PCU 3).
“Here in the Healthcare Center, if we need to prescribe magnesium sulfate, first thing
needed would be the medication, which is missing here.” (PCU 4)
“We don’t have the physical structure, we don’t even have epinephrine, we have nothing”.
(PCU 11)
“Here we have the resources, but not a lot is needed. The medication and a monitor are
required.” (M 13)
“There is no difficulty in dealing with this here, since we have the resources”. (M 11)
The organization of medical work in the PCU, specifically previous elective schedules and
the limited working period of these units (from 8 to 14 hours), were potentiating factors for
fear of using the medication:
“I believe that I don’t need to prescribe sulfate here, because you need to monitor the patient
frequently and here we cannot do this. I see other patients. I cannot stop caring for others to
care for this patient. It is not possible. . .”. (PCU 4)
“Here we have working hours, with a time to open and a time to close. I work shifts with a
time to enter and a time to leave. When my shift is over, I want to get out. Once I waited until
8:30 pm for the emergency mobile unit to arrive” (PCU 9).
“First, we would have to cancel patient schedule. Other patients would not understand.
What I mean is that we need to keep a close look at the patient. There is no other way to do it”.
(PCU 13)
Discussion
Our results identified that fear was the main emotional experience described by obstetricians
interviewed in PCUs. These healthcare workers withheld use of MgSO4 in severe preeclamp-
sia/eclampsia motivated by the risks of adverse drug events in a severely ill patient. Along with
the feeling of fear, other conditions revealed as concrete justifications for withholding drug
prescription were considered potentiating factors, e.g. unfamiliarity with the drug and its cor-
rect use, shortage of material, equipment and infrastructure, and deficient healthcare organiza-
tion in PCUs.
Despite evidence supporting that MgSO4 is the drug of choice for severe preeclampsia/
eclampsia [9], and studies in low-income and middle-income countries, such as Brazil, where
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use of MgSO4 in eclampsia is highly prevalent, maternal mortality rates from these disorders
remain elevated [13, 14]. The apparent paradox may derive from incorrect drug use as revealed
by this study. It was observed that obstetricians working in PCU do not prescribe the medica-
tion, but transfer this responsibility to professionals in maternity hospitals. Drug prescription
may be too late, worsening patient prognosis, along with none integrated healthcare between
primary facilities and referral centers [19].
Severe adverse events due to the use of MgSO4 are rare. Respiratory arrest, which is the
most feared event, occurred in 1% of all women with preeclampsia treated with MgSO4, estab-
lishing a high level of safety in clinical drug use [9]. Despite these rare events, some studies
searched for the ideal minimum therapeutic dose. Assessment of serum magnesium concen-
trations by the Zuspan and Pritchard drug regimens, Salinger et al. found that minimum dose
levels were much lower than those described as therapeutic [31]. Alternative low-dose regi-
mens have been studied and may be as safe and efficient as the current standard regimen.
These low doses of MgSO4 may contribute to a decreased perception of toxicity risk, increasing
proper and timely drug use. However, until scientific evidence is established, recommenda-
tions propose maintenance of standard regimens [32].
Another concern about the safety of MgSO4 administration is vigilant monitoring during
its use. The literature has sufficient evidence showing that clinical control is safe and the drug
may be administered in primary care [5, 33]. Despite these recommendations, in our study we
found that the lack of oximeter, multiparametric monitor, and other devices precluded MgSO4
prescription in the PCU. On the other hand, it was relevant that obstetricians also perceived a
shortage of attending professionals. Patient monitoring, which was not delegated to other
health professionals (nursing staff), became more difficult.
It is also necessary to recognize that lawsuits are among the aspects related to fear of drug
prescription. Health professionals attempt to themselves by seeking more technological
resources, referrals to other specialists and refusing to accept more critical cases. Those profes-
sionals avoid the responsibility for MgSO4 use, particularly in locations with low technological
density [33].
In Brazil, the fear of lawsuits has increased among physicians and this defensive practice
has become increasingly more common [34, 35]. Evidence-based medicine opposes defensive
medicine, since it guides clinical practice in a rational and updated manner. When accessible
to the physician, it becomes a powerful management tool to improve healthcare quality and
thus reduce health impairment [36]. Access to evidence-based rational medicine requires con-
tinuous update and insertion of this knowledge into daily clinical practice. Fear revealed by the
doctor and the supposed adoption of defensive practice were related to the lack of training for
the management of obstetric emergencies. Training is currently not guaranteed by health
administrations.
The development of professional skills, as well as improvement in physical structure, mate-
rial/equipment and primary care organization, lead to qualified clinical care. Safety in the diag-
nosis and treatment of maternal emergencies is enhanced, including MgSO4 for management
of severe preeclampsia/eclampsia. These components have also been identified by others in
low-income and middle-income countries [37, 38] with similar results.
The work process of the obstetrician, his feelings, perceptions and experiences should be
understood by investigating daily practice and dynamics when a diagnosis of severe pre-
eclampsia/eclampsia is made. Failure to prescribe MgSO4 may lead to actions that alter behav-
ior. Management of hypertensive emergencies could be improved, contributing to a reduction
in maternal mortality.
Our study has limitations. It is not completely generalizable, since it only referred to the
population studied in a specific workplace in the southeast of Brazil. On the other hand, the
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feelings identified in this study could possibly be experienced by other physicians in settings
that are similar to ours, or even with more severe limitations.
Conclusions
Obstetricians reported fear of prescribing MgSO4 in the PCU, based on the risks of severe
adverse events. In general, justifications for having fear were related to unavailability of appro-
priate material, equipment/ infrastructure, and the way maternal healthcare is organized in the
context of action. Skill development planning and periodic obstetrical training, especially con-
sidering safety of the drug, in addition to integration of the medical team in the work environ-
ment may contribute to reduce fear, broadening timely prescription and thus improving
quality of maternal healthcare.
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